Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.


Add photos to showcase Immatics’s culture


Add Immatics’s values

Insider experiences

Share your experience of working at Immatics


Leadership Houston

Arun Satelli
Associate Director, Discovery Group
Chih-Chiang Tsou
Principal Scientist Bioinformatics
Jessica Mosby
Senior Director, Human Resources & Operations
Jorge M. Rivas
Associate Director, Regulatory Affairs
Kerry Sieger
Director, QA/QC
Mamta Kalra
Director, CMC
Riky Tran
Director IT, Immatics US
Zoe Coughlin
Director, CMC

Leadership Munich

Ajla Hrle
Director Strategic Alliances
Anja Heuer
Corporate Communications Manager
Claudia Blattner
Director, Business Development & Partnering
Miriam Meyer
Senior Director, EU Regulatory Affairs
Wolfgang Flasche
Director, Intellectual Property

Leadership Tübingen

Andrea Mayer
Senior Director Clinical Operations & Clinical Development
Carolin Mauch
Associate Director, Financial Planning & Analysis
Claudia Wagner
Director Immunology
Daniel Lübberstedt
Vice President IT
Dominik Maurer
VP Immunology
Ephraim Hofsäß
Senior Director of SEC Reporting & Accounting
Frank Schwöbel
Associate Director, Preclinical Pharmacology & Pharmacokinetics
Heiko Schuster
Associate Director Target Discovery
Maria Poulada
Director Finance
Martin Hofmann
Associate Director Immunology
Martina Ott
Associate Director Target Validation
Norbert Hilf
VP, Translational Development
Oliver Schoor
VP, Target Research
Regina Mendrzyk
Director Immunology
Sabrina Kuttruff-Coqui
Senior Director Capital Markets & Business Planning
Sarah Missel
Senior Director Translational Development, R&D Strategy and Communications
Sebastian Bunk
Senior Director, Immunology
Sonja Dorner
Associate Director, CMC
Carsten Reinhardt
Managing Director and Chief Development Officer
Cedrik Britten
Chief Medical Officer
Edward Sturchio
General Counsel
Jordan Silverstein
Head of Strategy
Michael Mølhøj
Senior Director CMC Biologics
Rainer Kramer
Managing Director and Chief Business Officer
Steffen Walter
Chief Technology Officer
Toni Weinschenk
Chief Innovation Officer
Arnd Christ
Chief Financial Officer
Delfi Krishna
Senior Director Strategic Operations
Jessica Cordes
Senior Director Clinical Operations
Anja Urban
Director Clinical Operations
Andrea Mahr
Director, Companion Diagnostics
Tamara Louw
Senior Director Human Resources
William Johnson
Sr. Director, Facilities & Engineering
Michael Mehler
Director of Global Site Operations
Lana Pilja
Director Clinical Operations
Ulf-Hergen Westphal
Senior Director and Head of Clinical QA & QMS

Add your teams to show how people work together at Immatics

Add jobs to your org chart to show candidates who they’ll work with

Team announcement

Immatics Biotechnologies Announces Cedrik Britten, as Chief Medical Officer

Immatics Biotechnologies Announces Cedrik Britten, as Chief Medical Officer

Clinical-stage cancer immunotherapy provider Immatics Biotechnologies GmbH has announced the appointment of Cedrik Britten, MD, as Chief Medical Officer (CMO) effective June 1, 2020. In the role, Dr. Britten will be responsible for the global clinical development of Immatics’ pharmaceutical pipeline and will report directly to company CEO Harpreet Singh. “We are excited about Cedrik joining Immatics. He has an extensive background in cell therapy, translational oncology, and immunology, as well as great experience in leading clinical and preclinical development programs in immuno-oncology. His appointment will complement Immatics’ existing strengths and capabilities as we continue the clinical development of our targeted immunotherapies with an emphasis on treating solid tumors through our two therapeutic modalities, Adoptive Cell Therapy and TCR Bispecifics,” commented Dr. Singh. Dr. Britten brings over ten years of experience with drug development to the leadership team at Immatics. He joins the team after serving as Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline in the UK were he oversaw Oncology R&D and their cell therapy pipeline. Dr. Britten also previously served as the Vice President of R&D at German immunotherapy provider BioNTech. “Immatics is bringing together three synergizing core elements that attracted me: excellent science, powerful proprietary technology platforms for the discovery of relevant targets, and T cell receptors tailored for use across a range of therapeutic modalities and a vibrant corporate culture focused on serving patients in need. These three cornerstones have enabled Immatics to reach a dynamic stage of growth with four ongoing clinical trials and a promising pipeline of several product candidates in development,” said Cedrik Britten.